In light of the continued rapid progress in the development of new treatments for Hepatitis C infection, the World Health Organization (WHO) has issued updated treatment guidelines that encourage the transition to newer, more effective medicines that have the potential to cure more than 90% of people treated. Direct-acting antivirals (or DAAs) are more effective and easier to use than established treatment regimens.
Treatment with DAAs is short in duration (8–12 weeks), easy to take (as few as 1 pill per day), has few side effects, and results in a cure for more than 90% of people treated. This is a vast improvement from older treatments, which cured less than half of the people treated, required weekly interferon injections for up to 12 months, and often resulted in severe, sometimes fatal, side effects. (WHO Press Release 4-13-16)
“PharMedQuest Pharmacy Services has been servicing Hep C patients since 2010 and was one of the first pharmacies to get insurance approval for DAA use in patient treatment,” said Meera Hasolkar, Director of Pharmacy Group for PharMedQuest. “Treatment for patients managing Hepatitis C is done through our ACE program,” she added.
ACE is a proprietary clinical CRM program designed to help monitor and care for patients with complex disease states such as HIV and Hepatitis C. With ACE, we focus on the core three tenants of Attention, Care and Empowerment improving both the quality of care and patient satisfaction. PharMedQuest reviews a wide array of treatment guidelines to assess the best possible treatment outcomes for Hepatitis C patients on a case-by-case basis. More info on our ACE program is available here.
You can read the press release from WHO, issued on April 13th from Barcelona, Spain here: http://who.int/hepatitis/news-events/hepatitis-c-guidelines-2016-story/en/.